The proposed $686M merger between Amag Pharmaceuticals (NASDAQ:AMAG) and Allos Therapeutics (NASDAQ:ALTH) could be scuttled after two large shareholders of AMAG threaten to vote against the transaction. Reports say the investors are evaluating if a management shakeup or supporting a tender offer from MSMB Capital might be better options. AMAG +8.1% premarket.